The quantitative benefit of isolated, segmental, pharmacomechanical thrombolysis (ISPMT) for iliofemoral venous thrombosis  by Martinez Trabal, Jorge L. et al.
From the American Venous Forum
The quantitative benefit of isolated, segmental,
pharmacomechanical thrombolysis (ISPMT) for
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Background: Early thrombus removal in patients with iliofemoral deep venous thrombosis (IFDVT) reduces postthrom-
botic morbidity. Preserving valve function and relieving venous obstruction prevents deterioration of quality of life and
loss of economic potential. The preferred method for treating IFDVT is catheter-directed thrombolysis (CDT). Recently,
isolated segmental pharmacomechanical thrombolysis (ISPMT) has emerged as a treatment option for patients with
extensive IFDVT. The purpose of our study is to determine whether there are advantages to using ISPMT as the primary
treatment for patients with iliofemoral IFDVT and, if so, to quantify those advantages relative to CDT.
Methods: Forty-three patients with IFDVT were treated with percutaneous CDT between May 2003 and June 2007.
Twenty-one patients (27 limbs) were treated with CDT and 22 patients (25 limbs) were treated with ISPMT  CDT.
Demographics, extent of thrombus, procedural details, and thrombus resolution were recorded.
Results: Treatment time (55.4 vs 23.4 hours; P< .0001) and dose of rt-PA (59.3 vs 33.4 mg; P .0009) were decreased
and overall lytic success (60% vs 80%; P  .0016) increased with ISPMT. Adjunctive venoplasty and stenting,
complications, hospital length-of-stay (LOS), and intensive care unit LOS were similar between groups.
Conclusion: ISPMT offers more effective thrombus removal in less time and with a reduced dose of thrombolytic agent.
However, decreased treatment time did not translate into decreased hospital or ICU stay. Longer-term follow-up is
required to determine whether improved thrombus resolution translates to better functional outcome and reduced
postthrombotic morbidity. ( J Vasc Surg 2008;48:1532-7.)Iliofemoral deep venous thrombosis (IFDVT) is asso-
ciated with significant postthrombotic morbidity if treated
with anticoagulation alone.1-3 There is an increasing body
of evidence suggesting that thrombus resolution is associ-
ated with markedly improved outcomes. Studies of acute
deep venous thrombosis (DVT) treated with anticoagula-
tion alone show that when spontaneous clot lysis occurs,
especially if it occurs early, patients are likely to retain
normal valve function.4
A multicenter trial of venous thrombectomy plus arte-
riovenous fistula vs anticoagulation alone in patients with
IFDVT showed significant benefit in those randomized to
operative venous thrombectomy.5-7 A case-controlled co-
hort study of catheter-directed thrombolysis for IFDVT
demonstrated significantly better quality-of-life (QOL) at
16 and 22 months in patients successfully lysed compared
to patients treated with anticoagulation alone.8 A small
randomized trial of catheter-directed thrombolysis vs anti-
coagulation alone for IFDVT confirmed these prior obser-
vations.9 The Eighth American College of Chest Physi-
From the Sections of Vascular Surgerya and Interventional Radiology,b
Jobst Vascular Center, The Toledo Hospital.
Competition of interest: none.
Presented at the American Venous Forum Twentieth Annual Meeting, Feb
20-23, 2008, Charleston, SC.
Correspondence: Anthony J. Comerota, MD, Director, Jobst Vascular
Center, The Toledo Hospital, 2109 Hughes Dr, Suite 400, Toledo, OH
43606 (e-mail: marilyn.gravett@promedica.org).
0741-5214/$34.00
Copyright © 2008 Published by Elsevier Inc. on behalf of The Society for
Vascular Surgery.doi:10.1016/j.jvs.2008.07.013
1532cians’ (ACCP) consensus conference recommendations for
the management of venous thrombo-embolic disease rec-
ognized the potential benefit of a strategy of thrombus
removal in patients with IFDVT, and such a strategy is now
recommended for good-risk patients.10
Catheter-directed thrombolysis (CDT) has been used
for years in patients with extensive DVT with good results;
however, the dose of lytic agent required for treatment was
large and treatment times long.11-13 With advancing tech-
nology, mechanical techniques have been integrated with
catheter infusion approaches to lytic therapy with varying
success and enthusiasm. A number of studies have evalu-
ated pharmacomechanical techniques compared with per-
cutaneousmechanical techniques alone, demonstrating im-
proved outcomes with combined therapy.14-17
A promising new technique is isolated, segmental,
pharmacomechanical thrombolysis (ISPMT), which iso-
lates the segment of thrombosed vein to be treated between
two occluding balloons.18,19 A small dose of lytic agent is
infused into the target segment and the intervening cathe-
ter spins at 1500 revolutions per minute (RPM) for 15 to
20 minutes. Following aspiration of the liquefied and frag-
mented thrombus, the vein is re-evaluated and re-treated, if
necessary. If the vein is cleared of thrombus, the catheter is
repositioned to treat another thrombosed venous segment.
During the past 28 months, we have used this tech-
nique for the initial management of patients with IFDVT.
The purpose of the study is to quantify the benefit of adding
ISPMT to a strategy of thrombus removal compared to
CDT without ISPMT in patients with IFDVT.
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Forty-three consecutive patients with symptomatic IFDVT
in 52 limbs who were judged to be appropriate candidates
for CDT or ISPMT form the basis of this study and were
retrospectively reviewed following institutional review
board approval. From May 2003 to October 2005, 27
limbs (13 right, 14 left) in 21 patients were treated with
traditional CDT. Since October 2005, 25 limbs (7 right,
18 left) in 22 patients were treated with ISPMT using the
Trellis (Bacchus Vascular, Santa Clara, Calif) catheter, fol-
lowed by adjunctive CDT when necessary to clear persis-
tent thrombus. Six patients were treated with ISPMT alone
for IFDVT and 16 had ISPMT with CDT. Catheter-
directed thrombolysis was always used to clear thrombus
distal to the popliteal vein catheter entry site if present.
Recombinant tissue plasminogen activator (rt-PA) was
used in 93% of patients and urokinase in the remaining 7%.
The diagnosis of IFDVT was established with venous
duplex ultrasonography scan. Phlebography confirmed the
diagnosis in all patients. Most patients were evaluated for
the presence of a thrombophilia, and most had spiral CT
scans of the chest, abdomen, and pelvis to evaluate for
pulmonary emboli and underlying thoracic, abdominal, or
pelvic pathology which might be associated with their
thrombotic disorder.
Preoperative thrombus burden was quantified by
using a modification of the venous scoring method re-
ported by Mewissen, et al,11 who calculated a thrombus
score for seven venous segments. We included two addi-
tional segments (tibial and profunda femoris), for a total
of nine venous segments. The thrombus score was 0 for a
thrombus-free (patent) segment, 1 when there was a50%
luminal reduction by thrombus and/or stenosis, 2 for a
50% luminal reduction, and 3 for an occluded segment.
The total thrombus score was determined by totaling the
scores for the nine vein segments. Overall lytic success was
calculated by subtracting the final thrombus score from the
initial thrombus score and dividing by the initial thrombus
score.
Patient demographic and laboratory data were re-
corded, including age, gender, admitting diagnosis,
medical history, hospital length of stay (HLOS), inten-
sive care unit length of stay (ICU-LOS), hemoglobin,
hematocrit, and creatinine level. Additionally, extent of
thrombosis, treatment time, dose of lytic agent, thrombus
resolution, and adjunctive therapy were recorded. All com-
plications were documented, including bleeding, cardio-
pulmonary, and renal complications. Bleeding complica-
tions were defined as follows: Major, any evidence of
hemodynamic instability, serious distant bleeding, large
hematoma, or patients receiving blood transfusions associ-
ated with any of the aforementioned conditions; Minor,
puncture site bleeding, brief hemoptysis, 15% drop in
hemoglobin or hematocrit, blood transfusions due to he-
modilution, and minor bleeding at a prior operative site.
Cardiopulmonary complications were defined as docu-
mented acute myocardial infarction with enzyme elevation(troponins, creatine phosphokinase-MB isoenzyme [CPK-
MB]) and electrocardiogram (EKG) changes. Renal compli-
cations were defined as a doubling of baseline creatinine or
need for hemodialysis.
Intensive care monitoring was used for all patients
while receiving CDT. Systemic anticoagulation with hepa-
rin and vitamin K antagonist (VKA) followed lytic therapy
in all patients and was achieved with intravenous unfrac-
tionated heparin targeting an activated partial thrombo-
plastin time (aPTT) 2.0  control or enoxaparin 1
mg/kg subcutaneously every 12 hours. Length of oral
anticoagulation was determined on an individual basis. Leg
elevation, elastic compression, and intermittent pneumatic
compression were integral components of therapy both in
the hospital and following discharge.
TECHNIQUE
Ultrasound-guided access was obtained through an unin-
volved common femoral or popliteal vein, depending on the
location of the thrombus. If popliteal vein thrombus distal to
catheter entry or infrapopliteal thrombus existed, the poste-
rior tibial vein was cannulated for catheter-based lysis. After
baseline phlebography, the thrombosed segment was tra-
versed with a 0.035-inch guidewire. Catheter-directed
thrombolysis was performed by placing a multiside-hole
catheter for intrathrombus infusion. The rt-PA was diluted
to 0.01-0.02 mg per mL of saline solution and the infusion
rate was 1 mg per hour. Serial phlebography was obtained
tomonitor resolution, generally after each run of the Trellis
catheter, after other forms of mechanical intervention, and
every 12-16 hours of CDT.
When using ISPMT, the Trellis catheter was advanced
over a guidewire through an 8 Fr sheath to treat the
selected segment. Proximal and distal balloons, which can
be inflated to fit blood vessels from 5-16 mm (and can be
oversized), were inflated and 3-6 mg of rt-PA was infused
between the balloons in 6-8 mL of saline solution (Fig).
The wire between the balloons was activated and rotated at
1500 RPM for 20 minutes. Formed and fragmented
thrombus was aspirated with a 20-30 cc syringe. Repeat
segmental phlebography was performed prior to deflation
of the balloons, thereby reducing (or avoiding) systemic
exposure of the lytic and contrast agents, which was mon-
itored with fibrinogen levels and creatinine.
Statistical analysis. Mean lytic success was compared
in the two treatment groups by Student t test. The propor-
tion of patients in groups – complete lysis (74%), moder-
ate lysis (50-74%), and minimal lysis (50%) – was also
compared among the treatment groups using Fisher’s Ex-
act Test.
RESULTS
The etiology of DVT was apparent in most of our
patients. Thrombophilia evaluations were incomplete in
some due to anticoagulation and the issue of whether
results would alter recommendations for care. Thrombo-
philia was identified in 28% of patients (24% CDT, 32%
ISPMTCDT) and included AT III, factor V Leiden, and
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have a malignancy (24% CDT, 18% ISPMT  CDT),
including lymphoma, prostate, lung, andmetastatic cancer.
Other etiologies included May Thurner syndrome, retro-
peritoneal fibrosis, and Crohn’s disease, and 9% of patients
were thought to be idiopathic (Table I).
The two treatment groups were similar except for the
distribution of gender. The CDT group had significantly
more males, compared to the ISPMT  CDT group.
Interestingly, the 6 patients who were able to be treated by
ISPMT alone were all female (Table II).
Total thrombus scores were 13.1  5.7 vs 11.7  4.9
(P  .34) for CDT vs ISPMT  CDT, respectively. Caval
involvement was 52% vs 32%; bilateral involvement was
29% vs 14%, femoropopliteal 76% vs 55%, and tibial 57% vs
41% for CDT vs ISPMT  CDT patients, respectively.
None of these differences were significant.
There were no significant differences in pre-treatment
thrombus scores (P  .5). Overall lytic success, defined as
Fig. Vein segments treated with ISPMT using the Trelli
inflated proximal and distal balloons.
Table I. Etiology of DVT
Etiology
CDT
(n  21)
ISPMT  CDT
(n  22)
Total
(n  43)
Coagulopathy 5 (23.8%) 7 (31.8%) 12
Surgery 7 (33.3%) 3 (13.6%) 10
Cancer 5 (23.8%) 4 (18.2%) 9
Idiopathic 3 (14.3%) 1 (4.5%) 4
Pregnant 0 (0.0%) 1 (4.5%) 1
Anatomic 1 (4.8%) 6 (27.3%) 7
Total 21 22 43the amount of thrombus removed after lytic therapy, washighest in the ISPMT  CDT group (80%), and lowest in
the CDT group (60%). The increase in lytic success (ap-
proximately 20%) among the ISPMT  CDT group com-
pared to CDT alone was significant (P .002) (Table III).
Treatment time and lytic dose were also significantly
different between the two treatment groups (P  .01). The
average treatment time for CDT was 55 hours which was
significantly higher than ISPMT  CDT (P  .0001). Lytic
dose was higher in the CDT group compared to ISPMT 
CDT (59 units vs 40 units, P  .012). Although other
adjunctive therapy (rheolytic thrombectomy, ultrasound-
accelerated lysis, etc) was used more often in CDT patients,
the difference was not significant. HLOS (P  .69) and
ICU-LOS (P .92) were similar in both groups.
Venoplasty was performed in 90% of CDT patients and
87% of ISPMT  CDT patients, and stents were used in
eter (Bacchus Vascular, Santa Clara, Calif).Arrows show
Table II. Patient demographics and type and location of
DVT
CDT
(n  21)
ISPMT  CDT
(n  22)
ISPMT alone
(n  6)
Age 52.6 (17.6) 44.0 (21.0) 36.2 (16.8)
Onset of symptoms 12.7 (17.4) 14.6 (19.0) 18.5 (28.2)
Male gender* 14 (66.7%) 7 (31.8%) 0 (0.0%)
Acute on chronic 11 (52.4%) 13 (59.1%) 2 (33.3%)
Caval involvement 11 (52.4%) 7 (31.8%) 0 (0.0%)
Femoropopliteal 16 (76.2%) 12 (54.5%) 2 (33.3%)
Bilateral iliofemoral 6 (28.6%) 3 (13.6%) 0 (0.0%)
Tibial 12 (57.1%) 9 (40.9%) 2 (33.3%)
*P  .5.s cath45% of CDT patients and 59% of ISPMT CDT patients.
26.2)
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difference in the number of inferior vena caval filters used in
each group; 52% of CDT patients had vena caval filters
placed, with 64% of those filters placed prior to the current
hospital admission, and 54% of ISPMT  CDT patients
received caval filters. Caval filtration was used in patients
with nonocclusive clot in their cava and at the discretion of
the treating physician.
A 15% drop in hemoglobin/hematocrit (Hgb/Hct)
occurred in 19% of patients in both groups. Bleeding compli-
cations, most of which were mild, were no different between
groups (23% CDT vs 19% ISPMT  CDT, P  .99). The
need for blood transfusions was similar in both groups. Two
major complications occurred, one in each group. One CDT
patient developed acute renal failure because of hemoglobin-
uria and dye load following adjunctive rheolytic thrombec-
tomy, and one ISPMTCDTpatient developed a symptom-
atic puncture site hematoma requiring blood transfusions.
DISCUSSION
This analysis quantifies the benefit of ISPMTCDT vs
primary CDT. Significantly more thrombus was removed
with ISPMT in less than half the time and with 39% less
plasminogen activator. Since post-treatment anticoagula-
tion is standardized for both treatment groups, the reduc-
tion in persistent thrombus burden may result in less post-
thrombotic morbidity and risk of recurrence with ISPMT.
A weakness of this study is its retrospective design. Its
strength, however, lies in the fact that it is a single-center
Table III. Analysis of thrombus burden and lytic outcom
CDT vs CDT  ISPMT vs ISPMT only
CDT (
Patient thrombus burden and lytic outcomes
Per limb
Pre-treatment thrombus burden 13.1
Post-treatment thrombus burden 5.7
Overall lytic success 0.6
Complete lysis 3
Moderate 50-74 16
Minimal 50% 8
Per patient
Treatment time (hours) 55.4
Lytic dose 59.3
CDT (
Outcomes showing ISPMT-alone patient group
Per limb
Pre-treatment thrombus burden 13.1 (
Post-treatment thrombus burden 5.7 (
Overall lytic success 0.6 (
Complete lysis 3 (
Moderate 50-74 16 (
Minimal 50% 8 (
Per patient
Treatment time (hours) 55.4 (
Lytic dose 59.3 (experience, with the same physicians using both treatmentmodalities, practicing similar techniques, using the same
plasminogen activator, and attempting to achieve maximal
thrombus resolution.
Hull, et al,20 suggested that improvement in clot bur-
den should be considered by regulatory authorities as a
meaningful surrogate outcome measure for treatment tri-
als. Residual venous thrombus is an important risk factor
for recurrent DVT. Prandoni, et al,21 performed a prospec-
tive cohort study following acute DVT in patients with
venous ultrasound scan and showed that recurrent venous
thrombosis was more frequent in patients with residual
thrombus. Agnelli, et al,22 performed a clinical outcomes
based meta-analysis of randomized trials of thrombolysis
and showed that patients with a lower residual clot burden
have a lower frequency of recurrence. Since thrombin gen-
eration is related to clot burden23 and is required for
recurrent thrombosis, any technique that reduces residual
thrombus burden will likely have a meaningful clinical
benefit to patients. Achieving this endpoint quicker and
with less plasminogen activator is likely to improve the
safety of the technique. As our experience with ISPMT
developed, patients with traditional contraindications to
lytic therapy, such as surgical patients and pregnant women,
were considered and treated with catheter-based interven-
tions.
The amount of plasminogen activator used in the
ISPMT patients overestimates the amount of systemic ex-
posure, since most of the plasminogen activator solution
infused during ISPMT is aspirated. In a larger comparative
op) CDT vs CDT  ISPMT; (Bottom) subset analysis of
21) ISPMT  CDT (n  22) P value
11.7 (4.9) .34
3.0 (3.7) .0183
0.8 (0.2) .0016
%) 7 (28.0%) .077
%) 16 (64.0%)
%) 2 (8.0%)
) 23.4 (21.5) .0001
) 33.4 (24.7) .0009
1) ISPMT  CDT (n  16) ISPMT (n  6)
12.1 (5.1) 10.7 (4.4)
3.1 (4.1) 2.7 (1.9)
0.8 (0.2) 0.7 (0.2)
) 6 (31.6%) 1 (16.7%)
) 12 (63.2%) 4 (66.7%)
) 1 (5.3%) 1 (16.7%)
29.3 (21.3) 4.7 (4.6)
39.6 (24.4) 13.8 (13.9)e. (T
n 
(5.7)
(4.4)
(0.2)
(11.1
(59.3
(29.6
(21.3
(26.2
n  2
5.7)
4.4)
0.2)
11.1%
59.3%
29.6%
21.3)experience, one would expect to see fewer bleeding com-
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cation occurred with ISPMT, which was a popliteal punc-
ture site hematoma.
The 2008 ACCP consensus conference on themanage-
ment of venous thromboembolic disease recommends
CDT as a treatment option in good-risk patients with
IFDVT.10 They go on to suggest that the addition of
mechanical techniques to CDT may offer benefits to pa-
tients. Many physicians who treat IFDVT using a strategy
of thrombus removal incorporate mechanical techniques
during thrombolysis. However, it appears that percutane-
ous mechanical techniques alone (without a lytic agent) are
inadequate for successful thrombus resolution in most
patients.
Vedantham, et al,14 evaluated several mechanical
thrombectomy devices used as an adjunct to CDT. He
concluded that mechanical thrombectomy alone was inad-
equate and that pharmacologic thrombolysis significantly
improved outcomes. Bush, et al,16 drew the same conclu-
sions when they demonstrated more effective thrombus
extraction after adding a lytic agent to rheolytic thrombec-
tomy. Lin, et al,17 formalized their 8-year experience when
they reviewed 98 catheter interventions for acute DVT.
Forty-six of those were catheter-directed thrombolysis
alone and in 52 of them pharmacomechanical techniques
were used. Unlike our observations, they showed a signifi-
cant reduction in ICU stay and HLOS with pharmacome-
chanical techniques and a reduction in blood transfusions.
Interestingly, 60% of their patients undergoing pharmaco-
mechanical thrombolysis did not undergo phlebography.
Kasirajan, et al,15 reported their preliminary observa-
tions with rheolytic thrombectomy demonstrating that me-
chanical thrombectomy alone was inferior to the combina-
tion of pharmacomechanical thrombolysis. Parikh, et al,24
recently reported a multicenter experience of ultrasound-
accelerated thrombolysis using the EKOS LySus catheter
(EKOS Corp, Bothell, Wash). In 53 cases treated, com-
plete lysis (90%) occurred in 79% after a mean infusion
time of 22 hours and a 4% major complication rate. Multi-
ple lytic agents were used across the eight centers included
in this analysis. When attempting to evaluate the benefit of
the new technique, they compared their observed results to
a historical report by Grunwald and Hofmann,25 not to the
CDT experience of the participating investigators.
O’Sullivan, et al,18 reported results of ISPMT alone for
the management of acute DVT. Complete thrombus reso-
lution was observed in only 14%, which is similar to our
results (Table III). However, limiting intervention to
ISPMT alone underestimates its value in the overall treat-
ment scheme of patients with extensive DVT. ISPMT alone
will leave larger thrombus burdens than if used as an initial
approach to thrombus removal, with CDT or other tech-
niques added as needed. Combining pharmacologic and
mechanical techniques results in better overall lytic success
than the use of any mechanical or lytic technique alone, a
finding observed by a number of other authors.
It is now apparent that a strategy of thrombus removal,
when successful, reduces postthrombotic morbidity.26,27We anticipate that recurrent venous thromboembolic
events also will be reduced in successfully treated patients,
since residual thrombus burden is less.
The use of ISPMT improves lytic success and requires
less time and a smaller dose of lytic agent. It is a safe and
effective approach even in patients with traditional relative
contraindications for CDT. Therefore, ISPMT should ex-
pand the proportion of patients offered a strategy of throm-
bus removal.
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